Početna › Autoimune bolesti › Illinois › Chicago
Kliničke studije za Autoimune bolesti u gradu Chicago, IL
12 studija za Autoimune bolesti traži sudionike na lokacijama u gradu Chicago i okolici (unutar oko 30 milja). Otvorite studiju da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
U tijeku regrutacijaFaza 2
- University of Chicago, Chicago
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
U tijeku regrutacijaFaza 2/3
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients, Chicago
- Northwestern Memorial Hospital - Accepting Adult Patients, Chicago
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients, Chicago
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
U tijeku regrutacijaFaza 2
- University of Chicago, Department of Medicine: Rheumatology, Chicago
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
U tijeku regrutacijaFaza 1
- The University of Chicago Medical Center, Chicago
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
U tijeku regrutacijaFaza 1/2
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
U tijeku regrutacijaFaza 1/2
- University of Illinois Hospital & Health Sciences System, Chicago
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
U tijeku regrutacijaFaza 2/3
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
U tijeku regrutacijaFaza 1/2
- Northwestern Memorial Hospital, Chicago
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
U tijeku regrutacijaOpažajna studija
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- i još 2
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
U tijeku regrutacijaFaza 1
- Northwestern University, Chicago
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
U tijeku regrutacijaFaza 1/2
- Northwestern University, Chicago
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
- University of Chicago Medical Center, Chicago
Studije za Autoimune bolesti u drugim gradovima
- Houston, TX21 studija
- Washington, DC19 studija
- New York City, NY19 studija
- Philadelphia, PA16 studija
- Durham, NC15 studija
- Boston, MA13 studija
- Los Angeles, CA12 studija
- Dallas, TX9 studija
- Cleveland, OH8 studija
- Milwaukee, WI8 studija
- Atlanta, GA8 studija
- Portland, OR8 studija
Ostale studije u gradu Chicago
- Nemikrocelularni karcinom pluća61 studija
- Rak dojke58 studija
- Rak (sve vrste)51 studija
- Metastatski karcinom45 studija
- Rak prostate45 studija
- Debljina41 studija
- Rak pluća41 studija
- Rak jajnika36 studija
- Moždani udar34 studija
- Kolorektalni rak33 studija
- Srčano zatajenje31 studija
- Prekomjerna tjelesna masa28 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.